ASRS 2023: Annexon to share results of ARCHER Phase 2 trial for the treatment of geographic atrophy

News
Article

The presenter, Jeffrey S. Heier, MD, Director of the Retina Service and Retina Research, Ophthalmic Consultants of Boston, and an investigator in ARCHER will deliver the data on July 30, 2023.

Scientists in a laboratory consult a clipboard and record data. Image credit: ©Seventyfour – stock.adobe.com

Annexon, Inc. will present results from the ongoing ARCHER Phase 2 trial in patients with GA at ASRS. Image credit: ©Seventyfour – stock.adobe.com

Annexon, Inc. will present results from the ongoing ARCHER Phase 2 trial in patients with geographic atrophy (GA) at the American Society of Retina Specialists (ASRS) 2023 Annual Meeting. This meeting will take place July 28 – August 1, 2023 in Seattle, Washington.

The company’s presentation details are as follows:

  • Date and Time: Sunday, July 30, 2023 at 9:00 am PT
  • Title: Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration with Intravitreal ANX007: Results of the ARCHER Study
  • Presenter: Jeffrey S. Heier, MD, Director of the Retina Service and Retina Research, Ophthalmic Consultants of Boston, and an investigator in ARCHER
  • Session: Dry AMD Symposium 2

In addition to this presentation, the Annexon management will host a conference call, joined by Heier, on Monday, July 31, 2023 at 1:30 pm PT. The webcast and accompanying slides will be available under the Events & Presentations section on the Investors & Media page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days.

Reference:

1. Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023. Annexon Inc. July 24, 2023. Accessed July 25, 2023. https://www.biospace.com/article/releases/annexon-to-report-archer-phase-2-trial-results-in-geographic-atrophy-at-asrs-2023/

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.